학술논문
Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Document Type
Letter
Author
Source
Subject
*CHIMERIC antigen receptors
*SARS-CoV-2
*HIV seroconversion
*IMMUNE reconstitution inflammatory syndrome
*COVID-19
*
*
*
*
Language
ISSN
1042-8194
Abstract
Non-severe COVID-19 presentations occurred in 5/19 (26%) patients post CAR-T. Three patients were asymptomatic, and only one patient was hospitalized for 8 d, requiring ward-based oxygen support. Keywords: SARS-CoV-2; COVID-19; CAR-T EN SARS-CoV-2 COVID-19; CAR-T 1980 1984 5 08/22/22 20220801 NES 220801 CAR-T therapy for relapsed/refractory (r/r) B-cell cancers confers heightened susceptibility to infection due to cytopenias, impaired T-cell immune reconstitution, B-cell aplasia, and hypogammaglobulinemia [[1]]. We demonstrate that severe SARS-CoV-2 infection in patients post CAR-T had a devastating mortality impact: 86% (12/14) of patients died and notably 92% (11/12) were in CR or PR at the time of death. [Extracted from the article]